Abstract
The development of new treatments in the post-genomic era requires methods for safe delivery of foreign genetic information in vivo. As a transient, natural and controllable alternative to recombinant viruses or plasmid DNA (pDNA), purified or in vitro transcribed messenger RNA (mRNA) can be used for the expression of any therapeutic protein in vitro and in vivo. As it has been shown previously, the simple injection of naked mRNA results in local uptake and expression. We show here that this process, in the skin, can greatly be modulated according to the injection solution composition and blocked by an excess of competing nucleic acids or a drug affecting cytosolic mobility. Different cell types at the site of injection can take up the foreign nucleic acid molecules and the protein translated from this is detected for no more than a few days. To test this gene transfer method in humans, we produced in vitro transcribed mRNA under good manufacturing practice (GMP) conditions in a dedicated facility. After injection into the human dermis, we could document the translation of the exogenous mRNA. Our results pave the way toward the use of mRNA as a vehicle for transient gene delivery in humans.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Advances in COVID-19 mRNA vaccine development
Signal Transduction and Targeted Therapy Open Access 23 March 2022
-
Clinical and immunological effects of mRNA vaccines in malignant diseases
Molecular Cancer Open Access 15 March 2021
-
mRNA vaccine: a potential therapeutic strategy
Molecular Cancer Open Access 16 February 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout



References
Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465–1468.
Robinson HL, Hunt LA, Webster RG . Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993; 11: 957–960.
Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745–1749.
Boczkowski D, Nair SK, Snyder D, Gilboa E . Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465–472.
Carralot JP, Probst J, Hoerr I, Scheel B, Teufel R, Jung G et al. Polarization of the immunity induced by direct injection of naked globin UTR-stabilized mRNA vaccines. Cell Mol Life Sci 2004; 61: 2418–2424.
Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res 1995; 55: 1397–1400.
Granstein RD, Ding W, Ozawa H . Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol 2000; 114: 632–636.
Hoerr I, Obst R, Rammensee HG, Jung G . In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000; 30: 1–7.
Pascolo S . Messenger RNA-based vaccines. Expert Opin Biol Ther 2004; 4: 1285–1294.
Donnelly J, Berry K, Ulmer JB . Technical and regulatory hurdles for DNA vaccines. Int J Parasitol 2003; 33: 457–467.
Klinman DM, Takeno M, Ichino M, Gu M, Yamshchikov G, Mor G et al. DNA vaccines: safety and efficacy issues. Springer Semin Immunopathol 1997; 19: 245–256.
Forg P, von Hoegen P, Dalemans W, Schirrmacher V . Superiority of the ear pinna over muscle tissue as site for DNA vaccination. Gene Therapy 1998; 5: 789–797.
Lyons JC, Ross BD, Song CW . Enhancement of hyperthermia effect in vivo by amiloride and DIDS. Int J Radiat Oncol Biol Phys 1993; 25: 95–103.
Messiha FS . Neurotoxicity of chlorpromazine and modulation by amantadine as a function of mouse strain. Neurotoxicology 1991; 12: 571–581.
Uma DP, Satish Rao BS, Kamath R . A method to score micronuclei in vivo using cytochalasin B-induced cytokinesis block. Mut Res 1998; 401: 33–37.
Mehta RT, Hopfer RL, McQueen T, Juliano RL, Lopez-Berestein G . Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother 1987; 31: 1901–1903.
Benner SA . Extracellular ‘communicator RNA’. FEBS Lett 1988; 233: 225–228.
Acknowledgements
This work was supported by the Fritz-Bender Stiftung. JP was supported by the DFG Graduiertenkolleg ‘infektionsbiologie’ 685 of Tübingen.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Gene Therapy website (http://www.nature.com/gt)
Supplementary information
Rights and permissions
About this article
Cite this article
Probst, J., Weide, B., Scheel, B. et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther 14, 1175–1180 (2007). https://doi.org/10.1038/sj.gt.3302964
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302964
Keywords
- RNA-transfection
- DNA-transfection
- endosomes
- calcium
- GMP
This article is cited by
-
Advances in COVID-19 mRNA vaccine development
Signal Transduction and Targeted Therapy (2022)
-
The germinal centre B cell response to SARS-CoV-2
Nature Reviews Immunology (2022)
-
Delivery Strategies for mRNA Vaccines
Pharmaceutical Medicine (2022)
-
Bioengineering of Novel Non-Replicating mRNA (NRM) and Self-Amplifying mRNA (SAM) Vaccine Candidates Against SARS-CoV-2 Using Immunoinformatics Approach
Molecular Biotechnology (2022)
-
Advances in Nanoparticles for Effective Delivery of RNA Therapeutics
BioChip Journal (2022)